Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.64 |
| ▸ | POLB | P06746 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | BDKRB1 | P46663 | 14/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4339955 | 1.00 | ALDH1A1 (0.64) | ALDH1A1POLBMAPTKMT2ACYP3A4 | |
| SCHEMBL4344810 | 0.88 | ALDH1A1 (0.61) | ALDH1A1POLBMAPTKMT2ACYP3A4 | |
| SCHEMBL4344806 | 0.88 | ALDH1A1 (0.61) | ALDH1A1POLBMAPTKMT2ACYP3A4 | |
| SCHEMBL4331412 | 0.87 | ALDH1A1 (0.48) | ALDH1A1POLBMAPTKMT2ACYP3A4 | |
| SCHEMBL4331409 | 0.87 | ALDH1A1 (0.48) | ALDH1A1POLBMAPTKMT2ACYP3A4 | |
| SCHEMBL4342900 | 0.87 | ALDH1A1 (0.52) | ALDH1A1POLBMAPTKMT2ACYP3A4 | |
| SCHEMBL3534971 | 0.81 | ALDH1A1 (0.76) | ALDH1A1POLBMAPTKMT2ACYP3A4 | |
| SCHEMBL3534966 | 0.81 | ALDH1A1 (0.76) | ALDH1A1POLBMAPTKMT2ACYP3A4 | |
| SCHEMBL5982557 | 0.81 | ALDH1A1 (0.74) | ALDH1A1POLBMAPTKMT2ACYP3A4 | |
| SCHEMBL5982477 | 0.81 | ALDH1A1 (0.74) | ALDH1A1POLBMAPTKMT2ACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7612060-B2 | Triazoles and methods of use | AMGEN INC. (US) | 2009-11-03 | — | — | US | disclosed |
| US-20060100213-A1 | Triazoles and methods of use | AMGEN INC. (US) | 2006-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100213-A1 | Triazoles and methods of use | CYP3A5, CYP3A43, CYP2E1 | ALDH1A1 251/4885POLB 1815/4885MAPT 2181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.